RBM4 and lung cancer: Together, our findings reveal that the m6A reader YTHDC1-directed RBM4 aberrant splicing is triggered by nuclear AURKA, providing novel opportunities for targeted therapy of lung cancer by blocking nuclear oncogenic signaling.